Course Director: 
Dr. Kenneth Cohen
Series date: 
07/01/2017 - 12:00pm CDT to 06/30/2018 - 1:00pm CDT

Accreditation Statement

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement 

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Series location: 
Chicago, IL 60637
United States


Sessionsort descending Date
“DNA Repair Defects in Metastatic Castrate Resistant Prostate Cancer” and “Making the Most in Graft-vs-Host: Biomarkers & Novel Treatment Strategies for GVHD” 08/21/2017 - 12:00pm to 1:00pm
“Drug De-Development: An Opportunity to Reduce Costs of Cancer Care” 05/07/2018 - 12:00pm to 1:00pm
“EGFR Mutation-Positive Lung Cancer in 2018” 05/14/2018 - 12:00pm to 1:00pm
“Enhancing the Immune Response in Non-Small Cell Lung Cancer” and “Targeting Cellular Metabolism Through Modulation of BACH1 in Triple Negative Breast Cancer ” 10/02/2017 - 12:00pm to 1:00pm
“Evolving Role of High Dose Chemotherapy and Autologous Stem Cell Transplant in Myeloma” and “Defining Response: A Closer Look at Biomarkers to Predict Response to Checkpoint Blockade in Solid Tumors” 06/25/2018 - 12:00pm to 1:00pm
“Exploring Preneoplastic Progression and Heterogeneity of Lung, and Head & Neck Malignancies” 03/12/2018 - 12:00pm to 1:00pm
“Hepatocellular Carcinoma: Treatment Challenges and the Landscape of Investigational Therapeutics” 09/11/2017 - 12:00pm to 1:00pm
“Hypomethylating Agents in AML: Understanding Practice Patterns and Enhancing Therapeutic Benefit” and “Immune Related Adverse Events: When to Refer” 10/09/2017 - 12:00pm to 1:00pm
“Identifying Cancer Patients at High Risk for ER Visits and Hospitalizations: The Supportive Oncology Screener” and “Acute Promyelocytic Leukemia: Induction Therapy for the High Risk Patient” 10/16/2017 - 12:00pm to 1:00pm
“Liposarcoma: New Insights into Subtypes and New Treatment Directions” and “From Clonal Hematopoiesis to Hematologic Malignancy: Determining the Causes of Transformation” 03/26/2018 - 12:00pm to 1:00pm